Compare · IRIX vs TMDX
IRIX vs TMDX
Side-by-side comparison of IRIDEX Corporation (IRIX) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IRIX and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.56B, about 157.2x IRIX ($16.3M).
- Over the past year, IRIX is down 25.1% and TMDX is down 28.6% - IRIX leads by 3.4 points.
- Both names hit the wire about 4 times in the past 4 weeks.
- TMDX has more recent analyst coverage (18 ratings vs 0 for IRIX).
- Company
- IRIDEX Corporation
- TransMedics Group Inc.
- Price
- $0.95-9.41%
- $74.01-2.55%
- Market cap
- $16.3M
- $2.56B
- 1M return
- -20.07%
- -2.15%
- 1Y return
- -25.10%
- -28.55%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1996
- 2019
- News (4w)
- 4
- 4
- Recent ratings
- 0
- 18
IRIDEX Corporation
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest IRIX
- SEC Form 8-K filed by IRIDEX Corporation
- President and CEO Mercer Patrick was granted 100,000 shares, increasing direct ownership by 27% to 468,784 units (SEC Form 4)
- Chief Financial Officer Dizon Romeo R was granted 30,000 shares, increasing direct ownership by 23% to 163,284 units (SEC Form 4)
- Large owner Novel Inspiration International Co., Ltd. acquired 111,997 shares (SEC Form 4)
- IRIDEX Corporation filed SEC Form 8-K: Other Events
- Chief Financial Officer Dizon Romeo R covered exercise/tax liability with 2,691 shares, decreasing direct ownership by 2% to 133,284 units (SEC Form 4)
- President and CEO Mercer Patrick covered exercise/tax liability with 3,990 shares, decreasing direct ownership by 1% to 368,784 units (SEC Form 4)
- Chief Financial Officer Dizon Romeo R bought $1,110 worth of shares (975 units at $1.14), increasing direct ownership by 0.72% to 135,975 units (SEC Form 4)
- Chief Financial Officer Dizon Romeo R bought $1,909 worth of shares (1,675 units at $1.14), increasing direct ownership by 1% to 135,000 units (SEC Form 4)
- Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference
Latest TMDX
- Officer Corcoran Nicholas was granted 11,727 shares, increasing direct ownership by 39% to 41,558 units (SEC Form 4)
- Chief Financial Officer Hernandez Gerardo was granted 17,246 shares, increasing direct ownership by 117% to 31,935 units (SEC Form 4)
- President & CEO Hassanein Waleed H was granted 49,669 shares, increasing direct ownership by 41% to 171,093 units (SEC Form 4)
- TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH
- Director Gunderson Thomas J. exercised 19,285 shares at a strike of $2.21 and sold $722,377 worth of shares (9,624 units at $75.06), increasing direct ownership by 138% to 16,642 units (SEC Form 4) (for withholding tax)
- SEC Form 144 filed by TransMedics Group Inc.
- SEC Form SD filed by TransMedics Group Inc.
- Director Basile Edward M was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Gunderson Thomas J. was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Raines Merilee was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)